Sanjay Chanda
Corporate Officer/Principal at AN2 THERAPEUTICS, INC.
Net worth: 64 376 $ as of 2024-04-29
Profile
Sanjay Chanda is the founder of Auration Biotech, Inc. founded in 2014.
He is currently the Chief Development Officer at AN2 Therapeutics, Inc. since 2019 and at Cortene, Inc. since 2017.
Dr. Chanda's former jobs include Senior Vice President-Drug Development at Anacor Pharmaceuticals LLC from 2013 to 2016 and Chief Development Officer at Arch Oncology, Inc. from 2016 to 2017.
Dr. Chanda's education history includes undergraduate and graduate degrees from Birla Institute of Technology & Science and a doctorate from Northeast Louisiana University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0.09% | 2024-03-14 | 28,235 ( 0.09% ) | 64 376 $ | 2024-04-29 |
Sanjay Chanda active positions
| Companies | Position | Start |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-10-31 |
Cortene, Inc.
 Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Corporate Officer/Principal | 2017-01-31 |
Former positions of Sanjay Chanda
| Companies | Position | End |
|---|---|---|
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | 2017-07-31 |
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | 2016-09-30 |
Auration Biotech, Inc.
 Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Founder | - |
Training of Sanjay Chanda
| Birla Institute of Technology & Science | Graduate Degree |
| Northeast Louisiana University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
Auration Biotech, Inc.
Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Commercial Services |
| AN2 Therapeutics, Inc. | |
Cortene, Inc.
Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Health Technology |
- Stock Market
- Insiders
- Sanjay Chanda
